Molecular detection of extensively drug-resistant Salmonella Typhi and carbapenem-resistant pathogens in pediatric septicemia patients in Pakistan - a public health concern

To determine the prevalence of multidrug (MDR) and extensively drug-resistant (XDR) pathogens from pediatric blood samples In total, 4543 children's blood samples were processed in the BacT/ALERT system. Confirmation of the isolates and MIC was determined in VITEK  2 system. Molecular identific...

Full description

Saved in:
Bibliographic Details
Published in:Future microbiology 2021-07, Vol.16 (10), p.731-739
Main Authors: Qamar, Muhammad Usman, Ambreen, Atifa, Batool, Alia, Rasool, Muhammad Hidayat, Shafique, Muhammad, Khan, Adnan, Nisar, Muhammad Atif, Khalid, Anam, Junaid, Kashaf, Abosalif, Khalid Oa, Ejaz, Hasan
Format: Article
Language:English
Subjects:
Carbapenems - pharmacology
Child
Drug Resistance, Multiple, Bacterial
Humans
Pakistan - epidemiology
Public Health
Salmonella typhi - drug effects
Salmonella typhi - isolation & purification
Sepsis - diagnosis
Sepsis - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the prevalence of multidrug (MDR) and extensively drug-resistant (XDR) pathogens from pediatric blood samples In total, 4543 children's blood samples were processed in the BacT/ALERT system. Confirmation of the isolates and MIC was determined in VITEK  2 system. Molecular identification of , and was done by PCR. Of 4543 blood cultures, 458 (10%) were positive for bacterial growth and  Typhi (415; 90%) remained the primary pathogens. Antibiogram revealed 208 (50.1%) and 137 (33%) were MDR and XDR . Typhi, respectively. displayed 46% resistance to imipenem. One hundred twelve (81.7%) XDR Typhi were positive for , whereas 14 (66.6%) were found in carbapenem-resistant bacteria.  A high prevalence of MDR and XDR pathogens was found in peads blood culture.
ISSN:1746-0913
1746-0921
DOI:10.2217/fmb-2021-0036